Crohn’s Disease in America 2026
Crohn’s disease remains one of the most pressing chronic health challenges facing Americans today. As a form of inflammatory bowel disease (IBD), it causes persistent inflammation anywhere along the digestive tract — from the mouth to the anus — but most commonly strikes the end of the small intestine and the beginning of the large intestine. Unlike many acute conditions, Crohn’s disease is lifelong, cyclical in nature, and deeply disruptive, forcing millions of patients to navigate unpredictable flares, escalating medication regimens, and, in many cases, surgical intervention. According to the Centers for Disease Control and Prevention (CDC), estimates of IBD prevalence in the United States range from 2.4 to 3.1 million adults, with Crohn’s disease accounting for a significant and growing share of that burden. These numbers are not static — the prevalence of IBD is rising across nearly every demographic group in the country.
What makes the 2026 Crohn’s disease landscape particularly significant is the convergence of rising case counts, improving but still imperfect treatment options, and a mounting economic toll that strains both patients and the broader healthcare system. Biologic therapies have transformed outcomes for many, yet up to 80% of patients still fail to achieve remission on first-line biologics. Meanwhile, the condition disproportionately affects working-age Americans, contributing to absenteeism, disability claims, and lost productivity on a national scale. This article draws exclusively on verified data from US government agencies — including the CDC, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institutes of Health (NIH), and peer-reviewed research published in leading gastroenterology journals — to present a comprehensive and accurate picture of Crohn’s disease in the United States in 2026.
Crohn’s Disease Key Facts in the US 2026
Before diving into the statistical data, it is worth understanding some of the most striking and often counterintuitive facts about Crohn’s disease in America. These facts underscore the complexity of the condition and the wide-ranging ways it affects patients across age groups, demographics, and disease trajectories.
CROHN'S DISEASE KEY FACTS SNAPSHOT — US 2026
=============================================
Estimated US Cases ████████████████░░░░ ~1.5 million
IBD Adults (Total) ████████████████████ 2.4–3.1 million
Peak Onset Age ████████████░░░░░░░░ 20–29 years
Surgery Within 10 Yrs ████████████████░░░░ 30–55%
Annual Healthcare Cost ████████████████████ $8.5 billion (IBD)
Biologic Fail Rate ████████████████░░░░ Up to 80%
Smoking Risk Increase ████████████████░░░░ >2x higher risk
Pediatric IBD Cases ████░░░░░░░░░░░░░░░░ 100,000+ youth
| Key Fact | Detail |
|---|---|
| Estimated US Crohn’s cases | Approximately 1.5 million Americans (2024 estimate) |
| Total IBD prevalence | 2.4–3.1 million US adults (CDC, 2024) |
| Primary age of onset | 20–29 years (peak incidence group) |
| Second onset peak | Adults aged 50s–70s |
| Most common site affected | End of the small bowel (ileum) and start of the colon |
| Surgery requirement | 30–55% of patients require surgery within 10 years of diagnosis |
| Smoking risk factor | Active smokers are more than twice as likely to develop Crohn’s |
| Biologic therapy failure | Up to 80% of patients fail to achieve remission on biologics |
| Pediatric IBD | More than 100,000 Americans under age 20 live with IBD |
| Pediatric Crohn’s increase | 22% rise in pediatric Crohn’s prevalence since 2009 |
| Total IBD healthcare cost (2018) | $8.5 billion annually in the US |
| Prescribed medicine share of cost | 71% of total IBD healthcare expenditure |
| Serious psychological distress | 7% of IBD adults vs 3% without IBD |
| Sleep deprivation | 38% of IBD adults sleep fewer than 7 hours per night |
Source: Centers for Disease Control and Prevention (CDC), IBD Facts and Stats, June 2024; NIDDK, Crohn’s Disease Treatment, 2024; Crohn’s & Colitis Foundation, CDC-Funded Pediatric IBD Study, Gastroenterology, November 2024
Crohn’s disease carries a burden that extends well beyond gastrointestinal symptoms. The fact that 30 to 55% of patients require surgical intervention within a decade of diagnosis speaks to the severity and treatment-resistant nature of the condition for a large segment of the population. Surgery does not cure Crohn’s — it treats specific complications — meaning patients who undergo bowel resection or fistula repair may still face lifelong disease management, recurrence, and further procedures.
What is equally striking is the psychological and behavioral toll the disease exerts. Adults with IBD are twice as likely to experience serious psychological distress compared to the general population. They are also significantly more likely to fall short of physical activity guidelines and to suffer chronic sleep deprivation — factors that further compound their health challenges and reduce quality of life. The pediatric dimension should also not be overlooked: a landmark CDC-funded study published in November 2024 confirmed that Crohn’s disease in children has risen by 22% since 2009, signalling that this disease is increasingly affecting America’s youth at critical developmental stages.
Crohn’s Disease Prevalence by Race and Ethnicity in the US 2024
Understanding how Crohn’s disease prevalence varies across racial and ethnic groups is essential for identifying healthcare inequities and targeting resources effectively. Data from the CDC and published in Gastroenterology (2023) provides the most comprehensive national picture to date.
CROHN'S DISEASE & IBD PREVALENCE BY RACE/ETHNICITY — US 2024
=============================================================
(IBD Prevalence as % of population)
Non-Hispanic White ████████░░░░░░░░░░░░ 0.8%
Black █████░░░░░░░░░░░░░░░ 0.5%
Hispanic █████░░░░░░░░░░░░░░░ 0.5%
Asian American ████░░░░░░░░░░░░░░░░ 0.4%
Crohn's prevalence per 100,000 (all groups): 305 per 100,000
| Racial/Ethnic Group | IBD Prevalence (% of population) | Trend |
|---|---|---|
| Non-Hispanic White | 0.8% | Highest; long-established prevalence |
| Black Americans | 0.5% | Rising; APC of 5.0% for Crohn’s (Medicare data) |
| Hispanic Americans | 0.5% | Increasing in recent cohort studies |
| Asian Americans | 0.4% | Lowest; but also rising over time |
| Overall US (Crohn’s) | 305 per 100,000 person-years | Consistent upward trajectory |
| Overall US (IBD) | 721 per 100,000 person-years | Highest rates globally in North America |
Source: CDC, IBD Facts and Stats, June 2024; Lewis JD et al., Gastroenterology, 2023 (NIDDK/NIH-funded study)
Non-Hispanic White Americans continue to bear the highest burden of Crohn’s disease in the United States, with IBD prevalence at 0.8% of that population. However, the data reveals an important and often underreported trend: prevalence is rising fastest among minority groups. CDC data tracking Medicare beneficiaries found that the annual percentage change in Crohn’s disease prevalence among non-Hispanic Black patients was 5.0% — significantly outpacing the increase in White, Hispanic, and Asian populations. This signals that the traditional narrative of Crohn’s as primarily a disease of White Americans is rapidly evolving.
The overall US prevalence of Crohn’s disease at 305 per 100,000 person-years places the United States among the countries with the highest global disease burden. This figure, derived from the landmark NIH-funded study published in Gastroenterology, reflects the most rigorous national prevalence estimate available and forms the evidence base for federal public health planning. As racial disparities narrow, the total national caseload is set to increase further — making equitable access to biologic therapy and gastroenterology specialist care a critical public health priority.
Crohn’s Disease by Age Group and Gender in the US 2024
Age and sex are two of the most important epidemiological variables in understanding who develops Crohn’s disease and when. Research consistently shows that the disease has a bimodal age distribution and affects men and women at similar overall rates, though some patterns differ.
CROHN'S DISEASE INCIDENCE BY AGE GROUP — US 2024
=================================================
(Crude incidence rate per 100,000 person-years)
Age 1–19 ██░░░░░░░░░░░░░░░░░░ 6.5
Age 20–29 ████████████████████ 16.6 ← PEAK
Age 30–44 ████████░░░░░░░░░░░░ ~8.0 (estimated decline)
Age 45–64 ████░░░░░░░░░░░░░░░░ ~5.0 (second plateau)
Age 65+ ████████████░░░░░░░░ Higher prevalence (cumulative)
| Age Group | Key Statistic | Notes |
|---|---|---|
| 1–19 years | 6.5 per 100,000 person-years | Lowest incidence age group |
| 20–29 years | 16.6 per 100,000 person-years | Highest incidence — peak onset |
| Mid-20s | Peak incidence age | Most new diagnoses concentrated here |
| Mid-50s | Peak prevalence age | Cumulative case load peaks in this decade |
| Ages 45+ | Highest IBD prevalence | Prevalence rises with age (CDC) |
| Pediatric (<20) | 100,000+ US youth with IBD | CDC-funded 2024 study |
| Adult cases (global 7MM) | ~93% of total Crohn’s burden | Adults dominate case count |
| Pediatric cases (global 7MM) | ~7% of total burden | Approximately 141,300 pediatric cases (2024) |
Source: Tremaine WJ et al., Olmsted County Study (NIH-funded); CDC IBD Facts and Stats, June 2024; Crohn’s & Colitis Foundation, Gastroenterology, November 2024
The 20–29 age group bears the highest incidence burden, with 16.6 new Crohn’s cases per 100,000 person-years — more than twice the rate seen in teenagers. This peak in early adulthood is clinically significant because it strikes patients at a formative life stage, impacting education, career development, fertility decisions, and mental health. After the age of 29, incidence rates decline sharply, though prevalence continues to climb through middle age as existing patients accumulate in the population and require decades of ongoing care.
The pediatric dimension of Crohn’s is particularly alarming in the context of recent CDC-funded research. With more than 100,000 Americans under age 20 now living with IBD — and pediatric Crohn’s prevalence up 22% since 2009 — the long-term healthcare demands on this cohort are substantial. Children diagnosed with Crohn’s face a lifetime of disease management beginning in childhood or adolescence, with associated risks including growth delays, nutritional deficiencies, bone density loss, and psychological burden. The near-equal sex distribution at initial incidence gives way in adult life to a slight female predominance in hospitalization rates, a pattern confirmed across multiple national datasets.
Crohn’s Disease Hospitalization and Surgery Rates in the US 2024
Hospitalizations and surgical procedures represent the most acute and costly manifestations of Crohn’s disease, and tracking them over time provides a clear picture of disease severity and healthcare system impact.
CROHN'S DISEASE HOSPITALIZATIONS — US TREND
============================================
(Any-listed diagnosis, CDC/AHRQ National Inpatient Sample)
2003 ████████████░░░░░░░░ 120,209 (44.2 per 100,000)
2008 ████████████████░░░░ ~160,000 (estimated)
2013 ████████████████████ 196,480 (59.7 per 100,000)
SURGERY REQUIREMENT WITHIN 10 YEARS OF DIAGNOSIS: 30–55%
Small bowel resection rate declined: 4.9% (2003) → 3.9% (2013)
| Hospitalization / Surgery Metric | Statistic | Year / Source |
|---|---|---|
| Crohn’s-listed hospitalizations (2003) | 120,209 (44.2 per 100,000) | 2003, AHRQ NIS/CDC |
| Crohn’s-listed hospitalizations (2013) | 196,480 (59.7 per 100,000) | 2013, AHRQ NIS/CDC |
| Increase in hospitalization rate | +35.1% over the decade | CDC, MMWR 2017 |
| Surgery within 10 years of diagnosis | 30–55% of patients | NIDDK, 2024 |
| Small bowel resection rate | Declined from 4.9% to 3.9% | CDC, MMWR 2017 |
| Colorectal resection rate | Stable over the same period | CDC, MMWR 2017 |
| Fistula repair rate | Stable over the same period | CDC, MMWR 2017 |
| Peak hospitalization age group | 18–44 years (first-listed diagnosis) | AHRQ NIS |
Source: CDC, Morbidity and Mortality Weekly Report (MMWR), Vol. 66, April 2017; NIDDK, Crohn’s Disease Treatment, updated 2024; Agency for Healthcare Research and Quality (AHRQ), National Inpatient Sample
Crohn’s disease hospitalizations rose by a striking 35.1% between 2003 and 2013, from 120,209 to 196,480 annual hospital stays. This increase occurred despite the widespread introduction of biologic therapies during this period — therapies that were expected to reduce hospitalizations. The persistence of high inpatient volumes underscores the limitations of current treatment options for a significant segment of the Crohn’s patient population, particularly those with moderate-to-severe disease who do not achieve durable remission on available medications.
The surgical burden is equally stark. The NIDDK confirms that between 30% and 55% of Crohn’s patients require surgery within 10 years of their diagnosis — not to cure the disease, but to manage complications such as intestinal obstruction, severe fistulas, and abscesses. While the rate of small bowel resection declined modestly (from 4.9% to 3.9%), indicating some improvement from medical therapies in preventing the most common surgical procedure, colorectal resection and fistula repair rates remained unchanged — reflecting persistent severe complications that medicines cannot resolve. The 18–44 age group consistently records the highest hospitalization rates, confirming that the heaviest acute disease burden falls on working-age Americans.
Crohn’s Disease Treatment and Biologic Therapy Outcomes in the US 2025
Biologic therapies have fundamentally altered the treatment landscape for Crohn’s disease over the past two decades, yet the gap between potential and reality remains wide. The following data reflects the most current evidence on treatment response rates.
BIOLOGIC THERAPY OUTCOMES FOR CROHN'S DISEASE — 2025
=====================================================
(Based on clinical trial network meta-analysis, 55 trials, n=16,113)
Biologic-naïve patients achieving remission at week 52:
Ustekinumab ████████████████░░░░ 65%
Adalimumab ███████████████░░░░░ 61%
Infliximab ████████████████░░░░ ~60–65% (standard)
Overall: Up to 50% no response | Up to 80% fail to reach remission
Anti-TNF failure → IL-23 inhibitors (risankizumab) now preferred
| Treatment Metric | Statistic | Source / Trial |
|---|---|---|
| Biologic-naïve patients: no response rate | Up to 50% | CGH Journal, 2022 |
| Biologic-naïve patients: fail to achieve remission | Up to 80% | CGH Journal, 2022 |
| Ustekinumab remission at week 52 | 65% of patients | SEAVUE Trial |
| Adalimumab remission at week 52 | 61% of patients | SEAVUE Trial |
| Corticosteroid-free remission (dual biologic) | 50% of refractory patients | NIH/PMC, 2024 |
| Patients switching from anti-TNF to IL-23 inhibitors | Increasing practice | 2025 meta-analysis, 55 trials |
| First-line treatment resistance | >33% require second-line therapy | 2025 systematic review |
| CRP normalisation rate on first-line biologics | 67.2% of patients | PMC study, 2024 |
Source: Ungaro et al., Clinical Gastroenterology and Hepatology, 2022; SEAVUE Trial data; Gorski et al., Pharmacotherapy, 2025 (systematic review, 55 RCTs, n=16,113); NIH PubMed Central
The treatment gap in Crohn’s disease is one of the defining challenges for American gastroenterology in 2026. Despite the availability of multiple approved biologics — including anti-TNF agents (infliximab, adalimumab), vedolizumab, ustekinumab, and newer IL-23 inhibitors — up to 50% of patients show no meaningful response, and up to 80% fail to sustain remission over the long term. The landmark SEAVUE head-to-head trial found that both ustekinumab (65%) and adalimumab (61%) achieved clinical remission at week 52 in biologic-naïve patients, providing the clearest direct comparison of first-line options to date.
However, these rates apply to carefully selected trial populations, not the full spectrum of real-world Crohn’s patients. A 2025 systematic review of 55 randomised controlled trials involving 16,113 patients, published in Pharmacotherapy, confirmed that more than one-third of patients are resistant to first-line treatments and require escalation. For those who fail anti-TNF therapy, emerging evidence increasingly supports switching to IL-23 inhibitors such as risankizumab, which ranked highest for both induction and maintenance remission in this population. These treatment dynamics are reshaping prescribing patterns across the US and driving a substantial portion of the $8.5 billion annual IBD healthcare expenditure, with 71% of that sum now attributable to prescribed medications — dominated by high-cost biologics.
Crohn’s Disease Economic Burden in the US 2024
The financial cost of Crohn’s disease falls heavily on patients, insurers, employers, and the federal healthcare system. Understanding the full economic picture is essential context for policy decisions and resource allocation.
US CROHN'S DISEASE ANNUAL COSTS — 2024
=======================================
(Per patient per year, in USD)
Total IBD healthcare spend (2018) ████████████████████ $8.5 billion
Direct healthcare costs (CD) ████████████████░░░░ $17,463 higher vs non-IBD
Indirect costs (work loss) ████░░░░░░░░░░░░░░░░ $2,168 higher vs non-IBD
Year-of-diagnosis costs ████████████████████ $30,000 (initial year)
Ongoing annual care costs ████████████░░░░░░░░ $23,000 (post-stabilisation)
Prescribed medicine share: 71% | Inpatient: 18% | Office visits: 9% | ED: 2%
| Cost Category | Annual Amount (USD) | Source |
|---|---|---|
| Total US IBD healthcare costs (2018) | $8.5 billion | CDC IBD Facts and Stats, 2024 |
| Prescribed medicine share | 71% of total | CDC, 2024 |
| Inpatient care share | 18% of total | CDC, 2024 |
| Office-based visits share | 9% of total | CDC, 2024 |
| Emergency department visits share | 2% of total | CDC, 2024 |
| Direct healthcare costs (CD vs non-IBD) | $17,463 higher per patient/year | Tanveer et al., Journal of Medical Economics, 2020 |
| Indirect work-loss costs (CD vs non-IBD) | $2,168 higher per patient/year | Tanveer et al., 2020 |
| Cost in year of initial diagnosis | ~$30,000 per patient | Crohn’s & Colitis Foundation study, 2019 |
| Annual cost post-treatment stabilisation | ~$23,000 per patient | Crohn’s & Colitis Foundation, 2019 |
| Out-of-pocket cost (excluding premiums) | ~$2,213 per patient/year | Crohn’s & Colitis Foundation |
Source: CDC, IBD Facts and Stats, updated June 2024; Tanveer et al., Journal of Medical Economics, 2020 (Crohn’s & Colitis Foundation-affiliated data); Crohn’s & Colitis Foundation cost-of-illness report, 2019
The $8.5 billion annual US healthcare spend on IBD — of which Crohn’s disease accounts for a major portion — has been fundamentally restructured by biologic therapy. Prescribed medications now consume 71% of all IBD healthcare spending, a complete reversal from earlier eras when hospitalisation dominated costs. While this shift reflects the clinical success of biologics in keeping patients out of hospital, it also exposes a structural vulnerability: biologic drugs carry list prices often exceeding $20,000–$50,000 per year, and any disruption in insurance coverage or drug access can rapidly push patients into crisis.
The direct burden on individual Crohn’s patients is staggering. Compared to matched controls without IBD, Crohn’s patients incur $17,463 more in direct healthcare costs per year, plus $2,168 more in work-related productivity losses. In the year of initial diagnosis, costs spike to approximately $30,000 per patient — a figure that drops to roughly $23,000 annually once a treatment plan is established, according to Crohn’s & Colitis Foundation research. Even with insurance, out-of-pocket expenses average $2,213 per year for Crohn’s patients, compared to approximately $979 for people without the disease — a difference that imposes genuine financial hardship, particularly on young adults and those in lower-income brackets.
Crohn’s Disease Disability and Workforce Impact in the US 2024
Beyond direct healthcare costs, Crohn’s disease creates a heavy indirect burden through disability, absenteeism, and reduced workforce participation. These figures illuminate the full societal cost of the condition.
CROHN'S DISEASE WORK AND DISABILITY IMPACT — US 2024
=====================================================
SSA digestive disorder disability awards (2024): 120,609
Average SSDI monthly benefit (digestive system, 2024): $1,683.24
Employment rates in active moderate-to-severe CD:
Full-time employed ████████████░░░░░░░░ 48%
Part-time employed ███░░░░░░░░░░░░░░░░░ 13%
Unemployed ████████░░░░░░░░░░░░ 39%
Receiving disability █████░░░░░░░░░░░░░░░ 25%
IBD work productivity loss (2024 meta-analysis):
Absenteeism: 4.1 hours missed/week
Presenteeism: 3.9 hours impaired/week
| Disability / Workforce Metric | Statistic | Source |
|---|---|---|
| Digestive disorder SSA disability awards (2024) | 120,609 individuals | Social Security Administration, 2024 |
| Average SSDI monthly benefit (digestive, 2024) | $1,683.24 per month | SSA, 2024 |
| Maximum SSDI monthly benefit (2026) | $4,152 per month | SSA, 2026 |
| Full-time employment in active Crohn’s (moderate-severe) | 48% | ACCENT I trial analysis |
| Unemployed in active Crohn’s | 39% | ACCENT I trial analysis |
| Receiving disability compensation | 25% of Crohn’s patients studied | ACCENT I trial analysis |
| IBD absenteeism (missed work) | 4.1 hours per week | Meta-analysis, JCC, September 2024 |
| IBD presenteeism (impaired at work) | 3.9 hours per week | Meta-analysis, JCC, September 2024 |
| IBD adults experiencing serious psychological distress | 7% vs 3% in general population | CDC, 2024 |
Source: Social Security Administration (SSA) Annual Statistical Report, 2024; Lichtenstein et al., ACCENT I trial; Youssef et al., Journal of Crohn’s and Colitis, September 2024; CDC, IBD Facts and Stats, June 2024
The workforce impact of Crohn’s disease is severe and measurable. Among patients with moderately to severely active disease, only 48% hold full-time employment, with 39% unemployed and 25% already receiving disability compensation — numbers drawn directly from the pivotal ACCENT I clinical trial cohort. These statistics reveal that a disease primarily affecting people in their 20s, 30s, and 40s is effectively sidelining a significant proportion of those individuals from sustained workforce participation. In 2024, the Social Security Administration awarded benefits to 120,609 individuals with digestive system disorders, with an average monthly payment of $1,683.24 — a figure that, while providing essential support, falls far short of replacing lost income for most recipients.
The productivity losses are not confined to outright absenteeism. A comprehensive 2024 meta-analysis published in the Journal of Crohn’s and Colitis found that IBD patients miss an average of 4.1 hours of work per week due to their condition, while losing a further 3.9 hours per week to presenteeism — being physically present but too unwell to perform optimally. Together, these figures represent nearly a full working day lost every week to the disease. When multiplied across the estimated 1.5 million Crohn’s patients in the United States, the national productivity loss is enormous. The CDC also confirms that adults with IBD are significantly more likely to experience serious psychological distress (7% vs 3%) — a comorbidity that further compounds their ability to maintain employment and daily functioning.
Crohn’s Disease Risk Factors and Health Behaviours in the US 2024
Environmental and behavioural risk factors play a measurable role in both the development and progression of Crohn’s disease. The most current national data identifies several modifiable and non-modifiable contributors to disease risk and severity.
CROHN'S DISEASE RISK FACTOR PROFILE — US ADULTS 2024
=====================================================
(IBD adults vs general population — CDC 2024 data)
Smoking (former) ████████████████████ 26% IBD vs 21% non-IBD
Sleep <7hrs/night ████████████████████ 38% IBD vs 32% non-IBD
Below activity guideline ████████████████████ 50% IBD vs 45% non-IBD
Psychological distress ████████████████████ 7% IBD vs 3% non-IBD
Smoker risk multiplier ████████████████░░░░ >2x general population
Family history risk ████████████████░░░░ Significant genetic component
| Risk Factor / Health Behaviour | IBD / Crohn’s Population | General Population |
|---|---|---|
| Former smoker | 26% | 21% |
| Sleeps fewer than 7 hours/night | 38% | 32% |
| Falls short of aerobic activity guidelines | 50% | 45% |
| Serious psychological distress | 7% | 3% |
| Active smoker risk of developing Crohn’s | More than 2× higher | Baseline |
| Smoking effect on disease course | Worsens flares, impairs treatment | — |
| Family history | Strong genetic component | Lower risk without family history |
| Western diet (high fat/sugar, low fibre) | Associated with gut microbiome disruption | — |
| IBD prevalence highest in northern states | Regional variation documented | CDC |
Source: CDC, IBD Facts and Stats, June 2024; NIDDK, Crohn’s Disease Definition & Facts, 2024; Healthline/CDC NHIS data; Mínguez & Nos, Journal of Cell Immunology, 2024
Smoking stands out as the most clearly established modifiable risk factor for Crohn’s disease. Active smokers are more than twice as likely to develop Crohn’s as non-smokers, and those who already have the condition face worsened treatment outcomes, more frequent flares, and reduced rates of remission if they continue smoking. This association is distinct from ulcerative colitis, where smoking has a paradoxical, partially protective effect — a biological divergence that underscores the different immunological mechanisms driving these two IBD types.
Beyond smoking, the CDC’s IBD data reveals a constellation of behavioural and psychosocial disadvantages that cluster around Crohn’s patients compared to the general population. Adults with IBD are significantly more likely to suffer from chronic sleep deprivation (38% vs 32%), to fall short of recommended physical activity levels (50% vs 45%), and to experience clinically significant psychological distress (7% vs 3%). These findings do not simply reflect the difficulty of exercising or sleeping with active symptoms — they also indicate that Crohn’s disease creates a cycle in which poor health behaviours exacerbate disease severity, which in turn further undermines health behaviours. Addressing this cycle through integrated care models that combine gastroenterological, psychological, and lifestyle support is increasingly recognised as essential to improving long-term outcomes for Crohn’s disease patients in the United States.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
